Gain-of-function variants in SYK cause immune dysregulation and systemic inflammation in humans and mice
Lin Wang,Dominik Aschenbrenner,Zhiyang Zeng,Xiya Cao,Daniel Mayr,Meera Mehta,Melania Capitani,Neil Warner,Jie Pan,Liren Wang,Qi Li,Tao Zuo,Sarit Cohen-Kedar,Jiawei Lu,Rico Chandra Ardy,Daniel J. Mulder,Dilan Dissanayake,Kaiyue Peng,Zhiheng Huang,Xiaoqin Li,Yuesheng Wang,Xiaobing Wang,Shuchao Li,Samuel Bullers,Anís N. Gammage,Klaus Warnatz,Ana-Iris Schiefer,Gergely Krivan,Vera Goda,Walter H. A. Kahr,Mathieu Lemaire,Chien-Yi Lu,Iram Siddiqui,Michael G. Surette,Daniel Kotlarz,Karin R. Engelhardt,Helen R. Griffin,Robert Rottapel,Hélène Decaluwe,Ronald M. Laxer,Michele Proietti,Sophie Hambleton,Suzanne Elcombe,Cong-Hui Guo,Bodo Grimbacher,Iris Dotan,Siew C. Ng,Spencer A. Freeman,Scott B. Snapper,Christoph Klein,Kaan Boztug,Ying Huang,Dali Li,Holm H. Uhlig,Aleixo M. Muise,
DOI: https://doi.org/10.1038/s41588-021-00803-4
IF: 30.8
2021-03-29
Nature Genetics
Abstract:Spleen tyrosine kinase (SYK) is a critical immune signaling molecule and therapeutic target. We identified damaging monoallelic <i>SYK</i> variants in six patients with immune deficiency, multi-organ inflammatory disease such as colitis, arthritis and dermatitis, and diffuse large B cell lymphomas. The SYK variants increased phosphorylation and enhanced downstream signaling, indicating gain of function. A knock-in (SYK-Ser544Tyr) mouse model of a patient variant (p.Ser550Tyr) recapitulated aspects of the human disease that could be partially treated with a SYK inhibitor or transplantation of bone marrow from wild-type mice. Our studies demonstrate that SYK gain-of-function variants result in a potentially treatable form of inflammatory disease.
genetics & heredity